地舒单抗联合特立帕肽治疗绝经后骨质疏松的临床研究  

Clinical study on the combination of Denosumab and Teriparatide in the treatment of postmenopausal osteoporosis

作　　者：余黎吉 伍丹丹 杜晓敏 沈龙德[2] Yu Liji;Wu Dandan;Du Xiaomin;Shen Longde(Department of Gynecology,Fujian Medical University Affiliated Quanzhou First Hospital,Quanzhou Fujian 362000,P.R.China;Department of Obstetrics and Gynecology,Fujian Medical University Affiliated Quanzhou First Hospital,Quanzhou Fujian 362000,P.R.China)

机构地区：[1]福建医科大学附属泉州第一医院妇科,福建泉州362000 [2]福建医科大学附属泉州第一医院妇产科,福建泉州362000

出　　处：《中国计划生育和妇产科》2025年第1期84-86,91,共4页Chinese Journal of Family Planning & Gynecotokology

摘　　要：目的探讨地舒单抗联合特立帕肽对绝经后骨质疏松患者骨代谢、血清骨硬化蛋白(sclerostin,SOST)和骨桥蛋白(osteopontin,OPN)及骨折风险的影响。方法选取福建医科大学附属泉州第一医院2021年3月至2023年2月期间收治的180例绝经后骨质疏松患者作为研究对象,按照随机数字表法分为对照组(特立帕肽)90例,观察组(地舒单抗+特立帕肽)90例。连续治疗12个月后,对比两组骨代谢指标、SOST和OPN水平、骨密度和Oswestry功能障碍指数(Oswestry disability index,ODI)、骨折发生率。结果两组一般资料比较差异无统计学意义(P>0.05)。治疗后观察组骨代谢水平优于对照组,腰椎、股骨颈、全髋骨密度升高幅度大于对照组,ODI评分低于对照组,且总疗效率高于对照组(P<0.05);观察组骨折发生率较低,但与对照组相比差异无统计学意义(P>0.05)。结论地舒单抗联合特立帕肽能有效改善绝经后骨质疏松患者骨代谢和骨密度异常水平,调节SOST和OPN水平,提高患者日常生活能力,效果显著。Objective Exploring the effects of Denosumab combined with Teriparatide on bone metabolism,serum sclerostin(SOST),osteopontin(OPN),and fracture risk in postmenopausal osteoporosis patients.Methods 180 postmenopausal osteoporosis patients admitted to Quanzhou First Hospital Affliated to Fujian Medical University from March 2021 to February 2023 were selected as the study subjects.They were randomly divided into a control group(90 cases with Teriparatide)and an observation group(90 cases with Denosumab+Teriparatide)using a random number table method.After 12 months of continuous treatment,compared the bone metabolism indicators,SOST and OPN levels,bone density and Oswestry disability index(ODI),and fracture incidence between the two groups.Results There was no statistically significant difference in general information between the two groups(P>0.05).After treatment,the bone metabolism level of the observation group was better than that of the control group,and the increase in bone density of the lumbar spine,femoral neck,and total hip was greater than that of the control group,the ODI score was lower than that of the control group,and the overall treatment efficiency was higher than that of the control group(P<0.05).The incidence of fractures in the observation group was lower,but there was no statistically significant difference compared to the control group(P>0.05).Conclusion Denosumab combined with Teriparatide can effectively improve the abnormal level of bone metabolism and bone density in postmenopausal osteoporosis patients,regulate the level of SOST and OPN,and improve the ability of daily life of patients,with significant effect.

关 键 词：地舒单抗 特立帕肽 骨质疏松 绝经 骨代谢 骨折 

分 类 号：R711.51[医药卫生—妇产科学]